Mounjaro contains tirzepatide and is FDA-approved to improve blood sugar control in people with type 2 diabetes when used with diet and exercise. Tirzepatide activates GIP and GLP-1 receptors, which can support insulin release when blood sugar is elevated, decrease glucagon levels, slow stomach emptying, and reduce appetite. Mounjaro is not FDA-approved specifically for weight loss; Zepbound contains the same active ingredient and is approved for chronic weight management in qualifying individuals.

Potential benefits may include:

• Improved blood sugar and A1C levels
• Reduced hunger and food intake
• Greater fullness after eating
• Weight reduction in some patients
• Once-weekly administration

Results vary based on dosage, health conditions, treatment response, nutrition, physical activity, and other medications. Tirzepatide can also cause side effects and is not appropriate for everyone, making a complete medical evaluation important before treatment begins.
At Cape Fear Physical Medicine and Rehab, each patient’s medical history, weight-related concerns, current medications, and health goals are reviewed before tirzepatide is considered. Our team provides ongoing monitoring to evaluate progress, tolerance, possible side effects, and whether the treatment plan remains appropriate.

Weight loss with tirzepatide generally occurs gradually rather than immediately. Some individuals may notice reduced appetite or changes in eating patterns during the first few weeks, but meaningful changes on the scale often develop over several weeks or months. Treatment commonly begins with a low dose and is increased gradually, which allows the body time to adjust.

The rate of weight loss varies according to:

• Starting weight and metabolic health
• Dose and treatment duration
• Nutrition and physical activity
• Type 2 diabetes and other health conditions
• Medication tolerance and consistency

In a 72-week obesity trial using tirzepatide, average weight reductions ranged from approximately 15% to 20.9%, depending on the assigned dose. These long-term averages should not be interpreted as a guaranteed or uniform weekly rate.

At Cape Fear Physical Medicine and Rehab, progress is evaluated over time rather than judged by the first few injections. Our team may monitor weight trends, appetite, side effects, lifestyle habits, and related health measures to determine whether treatment is producing safe and meaningful progress.

There is no reliable amount of weight that every person can expect to lose during the first month. Early treatment is usually an adjustment period, and the starting dose is intended to introduce tirzepatide gradually rather than produce maximum weight loss immediately. Some people may lose weight during this period, while others may notice little change until treatment has continued longer.

Monthly progress can be affected by:

• Initial body weight

• Appetite response

• Dose-escalation schedule

• Eating and activity habits

• Type 2 diabetes or insulin resistance

• Other medications and medical conditions

• Fluid changes and treatment consistency

Clinical trials report average results over many months—not a guaranteed amount per month. In adults with obesity, tirzepatide produced substantial average weight reduction over 72 weeks, but individual outcomes varied considerably. Dividing a long-term trial result into equal monthly amounts would be misleading because weight loss is rarely linear. At Cape Fear Physical Medicine and Rehab, patients receive individualized goals based on their starting health, treatment response, and long-term needs. Our team reviews trends across follow-up visits and may adjust the plan when appropriate instead of expecting every patient to meet the same monthly number.

Mounjaro begins affecting blood sugar regulation and appetite-related pathways after treatment starts, but the timing of noticeable results differs among patients. Changes in appetite may be noticed within the early weeks, while measurable improvements in weight and metabolic health usually become clearer with continued weekly treatment and gradual dose adjustment.

Patients should not expect the full effect after the first injection. The Mounjaro prescribing information starts treatment at 2.5 mg once weekly and permits an increase after four weeks, with additional increases made gradually when appropriate. Weight-related clinical studies evaluated outcomes over many months, showing that treatment response develops progressively rather than all at once.

At Cape Fear Physical Medicine and Rehab, follow-up appointments help our team determine when treatment is beginning to work and whether it remains suitable. Progress may be assessed through appetite changes, weight trends, medication tolerance, health measurements, and the patient’s ability to follow sustainable nutrition and activity habits.

Dr. Meisha K. Abbasinejad, MD, personalizes Mounjaro treatment by reviewing each patient’s medical history, current medications, diagnosis, weight-related concerns, previous treatment efforts, and overall health goals. She also considers potential contraindications, medication interactions, and side-effect risks before deciding whether Mounjaro is clinically appropriate. Mounjaro contains tirzepatide and is FDA-approved for improving blood sugar control in adults with type 2 diabetes when combined with diet and exercise.

At Cape Fear Physical Medicine and Rehab, Dr. Abbasinejad monitors each patient’s response through follow-up appointments, including changes in appetite, weight, blood sugar when applicable, medication tolerance, and overall progress. Dosage adjustments are made gradually when appropriate to reduce gastrointestinal side effects, while nutrition, physical activity, and sustainable lifestyle habits may be incorporated into the individualized care plan. Contact us today for more information, or simply schedule an appointment online! We are conveniently located at 1540 Purdue Dr, Ste. 200, in Fayetteville, NC 28303. We serve patients from Fayetteville NC, Woodfield NC, Hope Mills NC, Fort Bragg NC, Eastover NC, and surrounding areas.